Literature DB >> 25769668

Induced circular dichroism as a tool to investigate the binding of drugs to carrier proteins: Classic approaches and new trends.

Daniele Tedesco1, Carlo Bertucci2.   

Abstract

Induced circular dichroism (ICD) is a spectroscopic phenomenon that provides versatile and useful methods for characterizing the structural and dynamic properties of the binding of drugs to target proteins. The understanding of biorecognition processes at the molecular level is essential to discover and validate new pharmacological targets, and to design and develop new potent and selective drugs. The present article reviews the main applications of ICD to drug binding studies on serum carrier proteins, going from the classic approaches for the derivation of drug binding parameters and the identification of binding sites, to an overview of the emerging trends for the characterization of binding modes by means of quantum chemical (QC) techniques. The advantages and limits of the ICD methods for the determination of binding parameters are critically reviewed; the capability to investigate the binding interactions of drugs and metabolites to their target proteins is also underlined, as well as the possibility of characterizing the binding sites to obtain a complete picture of the binding mechanism and dynamics. The new applications of ICD methods to identify stereoselective binding modes of drug/protein complexes are then reviewed with relevant examples. The combined application of experimental ICD spectroscopy and QC calculations is shown to identify qualitatively the bound conformations of ligands to target proteins even in the absence of a detailed structure of the binding sites, either obtained from experimental X-ray crystallography and NMR measurements or from computational models of the complex.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Biorecognition; Carrier proteins; Drug binding; Induced circular dichroism; Quantum chemistry

Mesh:

Substances:

Year:  2015        PMID: 25769668     DOI: 10.1016/j.jpba.2015.02.024

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  6 in total

1.  Liposomal Formulations of a New Zinc(II) Complex Exhibiting High Therapeutic Potential in a Murine Colon Cancer Model.

Authors:  Nádia Ribeiro; Melissa Albino; Andreia Ferreira; Cristina Escrevente; Duarte C Barral; João Costa Pessoa; Catarina Pinto Reis; Maria Manuela Gaspar; Isabel Correia
Journal:  Int J Mol Sci       Date:  2022-06-16       Impact factor: 6.208

2.  Induction of axial chirality in divanillin by interaction with bovine serum albumin.

Authors:  Diego Venturini; Aguinaldo Robinson de Souza; Ignez Caracelli; Nelson Henrique Morgon; Luiz Carlos da Silva-Filho; Valdecir Farias Ximenes
Journal:  PLoS One       Date:  2017-06-02       Impact factor: 3.240

3.  Methyl divanillate: redox properties and binding affinity with albumin of an antioxidant and potential NADPH oxidase inhibitor.

Authors:  Debora Naliati de Vasconcelos; Angélica Nakagawa Lima; Eric Allison Philot; Ana Lígia Scott; Izabelle Amorim Ferreira Boza; Aguinaldo Robinson de Souza; Nelson Henrique Morgon; Valdecir Farias Ximenes
Journal:  RSC Adv       Date:  2019-06-26       Impact factor: 4.036

4.  Investigation on the chirality mechanism of chiral carbon quantum dots derived from tryptophan.

Authors:  Yingying Wei; Lin Chen; Junli Wang; Xuguang Liu; Yongzhen Yang; Shiping Yu
Journal:  RSC Adv       Date:  2019-01-25       Impact factor: 3.361

5.  Oxidative Alteration of Trp-214 and Lys-199 in Human Serum Albumin Increases Binding Affinity with Phenylbutazone: A Combined Experimental and Computational Investigation.

Authors:  Luiza de Carvalho Bertozo; Ernesto Tavares Neto; Leandro Cristante de Oliveira; Valdecir Farias Ximenes
Journal:  Int J Mol Sci       Date:  2018-09-21       Impact factor: 5.923

6.  Optimization and Development of Albumin-Biopolymer Bioconjugates with Solubility-Improving Properties.

Authors:  Zsófia Edit Pápay; Sabrina Magramane; Márton Király; Petra Szalkai; Krisztina Ludányi; Péter Horváth; István Antal
Journal:  Biomedicines       Date:  2021-06-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.